RespireRx Pharmaceuticals — Investor Presentation (September 2016)
39 slides from RespireRx Pharmaceuticals's investor presentation, Sep 12, 2016
Slide 1: RespireRx Pharmaceuticals Inc.
DR) RespireRx Pharmaceuticals Inc Pe orcas]
Slide 2: Forward Looking Statements
Forward Looking Statements (CQ RespireRx The matters discussed in this presentation that are not historical facts are “forward- looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and we intend that such forward-l
Slide 3: Breaking News
Breaking News Odres i o September 12, 2016 Press Release Positive top-line results from CX1739 Duke clinical trial in Opioid-induced Respiratory Depression o September 1, 2016 Press Release Implementation of 325 to 1 reverse split of common stock o Sets the stage for potential financing and Up-Listi
Slide 4: Breath is the universal factor of life (quote)
"Breath is the universal factor of life. We are born the first time we inspire, and we die the last time we expire. Breath is life itself. In Sanskrit the same word means both breath and life." wee Abbot George Burke
Slide 5: Company Focus
Company Focus (od RespireRx © Sleep Apneas = Dronabinol for Obstructive Sleep Apnea (OSA) = Ampakines for Central Sleep Apnea (CSA) Drug-induced Respiratory Depression (RD) - Ampakines = Acute use ~ surgical anesthesia/sedation * Semi-acute use — post-surgical pain management with opioids * Chronic
Slide 6: Innovative Medicines for Respiratory Diseases
Innovative Med es for Respiratory Diseases (> RespireRx o Two proprietary, small molecule platforms o Three Phase 2 developmentprograms » Additional pre-clinical programs Focus on blockbuster markets with unmet clinical needs » More than 120 + patents and patent applications Multiple opportunities f
Slide 7: Respiratory Diseases Product Pipeline
RespireRx Respiratory Diseases Product Pipeline A Compound | Indication Preclinical | Phase 1 Phase 2 Dronabins | Obstuctve Step Aores |S a ———{ oxen opeitnaieat RO — ——§ ont opbitnaicad RO oxrouz ong —
Slide 8: Translational Approaches to Respiratory Disorders - A Short Course
Translational Approaches to Respiratory Disorders - . A Short Course OQ RespireRx \ * Brain stem nuclei that regulate breathing contain opiate and AMPA glutamate receptors that inhibit and a7 excite, respectively “i ——— + Ampakines act as positive, allosteric modulators of the easel AMPA-type glutam
Slide 9: CX1739: A Third Generation, Oral Ampakine
€X1739: A Third Generation, Oral Ampal Phase 2 Re © Targeted Indications = Central Sleep Apnea (CSA) = Reversal and prevention of opioid-induced Respiratory Depression = Combination formulation with an opioid for treatment of chronic pain © Stage of Development = Successfully completed four Phase 1
Slide 10: CX1739: Phase 2A in Opioid-Induced Respiratory Depression
CX1739: Phase 2A in Opioid-Induced Respiratory Depression ®)RespireRx Protocol Antagonism of Remifentanil-Induced Respiratory Depression by CX1739 in Two Clinical Models of Respiratory Depression Randomized, Blinded, Placebo-controlled, Cross-Over with Dose Escalation 17 subject received and complet
Slide 11: CX1739: Phase 2A — Overall Study Design
€X1739: Phi - i ase 2A — Overall Study Design RespireRx (AQ RespireRx ‘STAGE1 ‘STAGE 2 Double-biind, Placebo-Controlled Crossover Open-label, DoseAscending — Weeks Wake 1, a
Slide 12: CX1739: Phase 2A — Daily Protocol
CX1739: Phase 2A — Daily Protocol C . Placebo x1739 REMI 1 bolus injection Model of acute overdose REMI 2— continuous infusion Model of chronic oral use — I sj 3.0 35 4 RespireRx sees sates 2
Slide 13: CX1739: Phase 2A — Safety
CX1739: Phase 2A — Safety OQ RespireRx Phormaceuticals Ine SAFETY DATA T. + CX1739 was safe and well : tolerated with no SAEs ent + Most frequent AEs were nausea, vomiting, headache and dizziness, all of which are . 2 | ‘common sideeffects of opioids 39 of 49 AEs occurred after remifentanil Number o
Slide 14: CX1739: Phase 2A REMI Single Subject
€X1739: Phase 2A REMI 1 Single Subject . Model of Acute Opiate Overdose cResplrekx ‘gure 1. kfects of Remifentanilon Respiatoy Rater ‘Pretreatment with Macebo.orCX1729 Fei no eal © After acute, bolus injection, remifentanil produced a rapid and dramatic decline in breathing © Considerable variabilit
Slide 15: CX1739: Phase 2A REMI1 — Model of Acute Opioid Overdose
CX1739: Phase 2A REMI1 —Model of Acute Opioid Overdose RM Reyutnalieg Primary Endpoint Met ° = Significant decline in time . to respiratory recovery for z 300mg vs placebo = Significant proportion of responders at one or more 4 doses of CX1739 (13 out of 15, p<.005, z test) 9<002 Recovery Time (minu
Slide 16: CX1739: Phase 2A REMI2 — Model of Chronic Opiate Use
CX1739: Phase 2A REMI 2 — Modelof Chronic Opiate Use OQ RespireRx Phormaceuticals Ine @ Primary Endpoint Met = CX1739 produced a statistically significant dose-related diminution ~ inthe respiratory = i depression produced by remifentanil erent changefrom aaine é 16
Slide 17: Central Sleep Apnea (CSA)
Central Sleep Apnea (CSA) Cd Respi o Lack of drive from the brain to breathe during sleep o CSA Patients = 70% of chronic narcotic users = Up to 40% of heart failure patients = 5% of sleep apnea patients are idiopathic No medicine or device is approved for CSA 7
Slide 18: CX1739: Completed Phase 2A in Sleep Apnea — Single Dose
CX1739: Completed Phase 2A in Sleep Apnea ~ Single Dose RespireRx [BAN ssl a beri Design Randomized double-blind, placebo-contoled study Population | 20 adullswith alliypos of moderate w severe sleep apnea (16 given OX1739;4 given Placebo) Dosing Each subjedt received eifer placebo ora single dose o
Slide 19: Patient Selection: CX1739 More Effective in Mixed and Central Sleep Apneas
Patient Selection: CX1739 Was More Effective in . Treating Mixed and Central Sleep Apneas OQ RespireRx Obstructive Apneas Mixed Apneas Central Apnea Apnea index (Eventsinr) Apnea Index (eventsinn (ete at, 2010)Can Paanmacn!Thec 8712} 204-1 19
Slide 20: CX1739: Proposed Phase 2 in Sleep Apnea — Multiple Dose
X1739: Proposed Phase 2 in Sleep Apnea — Multiple Dose RespireRx Evaluation of CX1739 for the Treatment of Central Sleep Apnea in Patients on Chronic Opioid Therapy Protocol + Randomized, Blinded, Placebo-controlled, Multiple Dose Study at Mutiple Sites Design + Subjects with a documented history of
Slide 21: CX717: Second Generation Oral Ampakine
CX717: Second Generation Oral Ampakine in Phase 2 © Targeted Indications * Spinal Cord Injury = Combination formulation with an opioid for treatment of chronic pain © Stage of Development = Completed 6 Phase 1 and 4 Phase 2 studies = Two positive Phase 2A trials in opioid-induced RD Intellectual Pro
Slide 22: CX717: Spinal Cord Injury
€X717: Spinal Cord Injury CQ) RespireRx Incidence Estimated 276,000 people with SCI in the US, with 12,000 new cases per year Eligible for Orphan Status Breathing problems are substantial after SCI ‘Approximately half of all SCls occur in the cervical region, leading to increased morbidity and morta
Slide 23: CX717 — Animal Models of Spinal Cord Injury
CX717 — Animal Models of Spinal Cord Injury OQRespireRx Unilateral hemi-transections at the level of the 2" cervical vertebra are performed on rats and electrical activity is recorded from phrenic nerves, which innervate the diaphragm and contribute to the regulation of breathing. ' Phrenic bursting
Slide 24: CX717 Prevents Opioid-induced Respiratory Depression in Humans
CX717 Prevents Opioid-induced Respiratory . Depression in Humans — Target Engagement OQ RespireRx 16 NS “ Pixcebo r —= eexr7 <2 z $ spot is ag NS- Not Signeant a 4 D prea Ce eta eta 2010 Paras The 972: . Baseline +Alfentanil_+Naloxone Alfentanil reduced breathing rate & produced Respiratory Depressi
Slide 25: CX717: Proposed Phase 2 in Spinal Cord Injury — Multiple Dose
CX717: Proposed Phase 2 in Spinal Cord Injury — Multiple Dose Re spireRx Evaluation of CX717 for the Treatment of Breathing Disorder in Patients with Protocol {514 Design _| Randomized, Blinded, Placebo-controlled, Ascending Dose Study ; BID doses of placebo, 250 mg, 500 mg and 750 mg of CX717 daily
Slide 26: Obstructive Sleep Apnea
Obstructive Sleep Apnea CQ RespireRx Sleep Apnea = Repetitive episodes of airflow cessation (apnea) or reduction (hypopnea) for more than 10 seconds during sleep = Three types: Obstructive, Central & Mixed The Sleep Apnea Market is Large = 18 million U.S. adults suffer from moderate or severe sleep
Slide 27: Dronabinol: Breakthrough Treatment for OSA
ronabinol: Breakthrough Treatment for OSA CQ RespireRx © Mechanism of Action = Dronabinol is (delta 9) THC, a cannabinoid agonist © Background = Schedule II! drug available by prescription, with a low risk of addiction = Approved for the treatment of anorexia in AIDS patients and nausea and vomiting
Slide 28: Completed Phase 2A Dronabinol in OSA
| Completed Phase 2A Ti ronabinol in OSA (AyRespireRx © Randomized, double-blind, placebo-controlled dose escalation study in 22 patients with OSA © Placebo (N=5) or dronabinol (N=17) for 21 days = 2.5, 5 and 10 mginight studied with weekly dose escalation » Overnight polysomnogram (PSG) at baseline
Slide 29: Dronabinol Proven to Reduce Apnea in OSA Subjects
Dronabinol Proven to Reduce Apnea in OSA Subjects CX Resp ireRx P=0.17 Index (AHI) Dronabinol Placebo ApnealHypopni: Pret tn anes B H 29
Slide 30: Apnea Suppression as a Function of Dose and Time
Apnea Suppression as a Function of Dose and Time (CQ RespireRx satversus Basalice SE eae ae Be be 17 net9 “8 ‘The plasma half-life of dronabinol is 2-4 hours. tathait 30
Slide 31: Completed Dronabinol Phase 2B Clinical Trial in OSA
Completed Dronabinol Phase 2B Clinical Trial in OSA (> RespireRx Sponsored and led by U of Illinois 4 major centers, fully funded by NIH Doses: Placebo, 2.5 mg, 10 mg qd 6 weeks dosing Trial completed Data expected Q4/2016 Meet with FDA after trial completion to determine registration path forward 3
Slide 32: The Dronabinol Opportunity
The Dronabinol Opportunity QRespireRx Impact on Patient Commercial Opportunity First medicine available for OSA Ease of Use/Better Patient Compliance Low cost Safe and effective Potential for better cardiovascular ‘outcomes Changes the nature of OSA treatment Broadly expands prescriber base from sle
Slide 33: Protecting Dronabinol in the Market
Protecting Dronabinol in the Market (> RespireRx o Issued Method-of-Use patent for dronabinol in OSA = Expires in 2025 o Schedule Ill drug: off-label use monitored by US government, discouraging generic manufacturers from selling off-label o Offlabel use of generics and medical marijuana are not cov
Slide 34: Respiratory Diseases Product Pipeline
Respiratory Diseases Product Pipeline A RespireRx Compound | Indication Preclinical | Phase 1 Phase 2 Prorat — | Oostucre Seep Ape | Centaiseeponea cxir9 opeitnaieat RO Sonata pry on opbitnaicad RO x94 rg duced RO wey —= 34
Slide 35: Development Milestones
Development Milestones OQ RespireRx 4azo16 | 102017 | 202017 | 3az017 | 42017 | 102018 (ox1739 RD Clinical Tal at Duke Central Sleep Apnea Ginical Trial Formulation, PK and ADME Cu FDA Regulatory Spinal Cord Injury Clinical Trial ‘AmpakinelOpioid Combination Formulation Fomulation Design Phase | Gin
Slide 36: Capital Structure & Market Metrics
Capital Structure (rounded) & Market Metrics Ore spireRx Total as of September 6, 2016 (unless otherwise noted) Post Reverse Split ‘Common Stock 2,019,000 ‘Common Stock Equivalents of Convertible Notes-pro forma to 29,000 September 15, 2016 ‘Common Stock Equivalents of al Options and Warrants Grante
Slide 37: Management and Directors
Management and Directors (> RespireRx James Manuso Amold Lippa Jeff Margolis Robert Weingarten Richard Purcell Katie MacFarlane James Sapirstein John Greer President, CEO & Vice Chairman CSO & Chairman VP, Secretary/Treasurer, Director CFO, Director Senior VP, R& D Director Senior VP, Napo Pharmaceu
Slide 38: Innovative Medicines for Respiratory Diseases
Innovative Med: es for Respiratory Diseases (> RespireRx o Two proprietary, small molecule platforms » Three Phase 2 development programs o Additional pre-clinical programs Focus on blockbuster markets with unmet clinical needs o More than 120 + patents and patent applications Multiple opportunities
Slide 39: RespireRx Pharmaceuticals Inc.
DR) RespireRx Pharmaceuticals Inc Pe orcas]
RespireRx Pharmaceuticals — Investor Presentation (September 2016) on 6ix